0.38%
-3.40%
28.02%
11.97%
0.28%
-44.56%
3.33%
AI Spotlight on DMP
Company Description
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally.It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts.The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products.
It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands.In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop.Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics.
It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores.The company was founded in 1991 and is headquartered in Grünwald, Germany.Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Market Data
| Last Price | 39.75 |
| Change Percentage | 0.38% |
| Open | 39.65 |
| Previous Close | 39.6 |
| Market Cap ( Millions) | 2140 |
| Volume | 19008 |
| Year High | 41.85 |
| Year Low | 30.15 |
| M A 50 | 38.67 |
| M A 200 | 35.63 |
Financial Ratios
| FCF Yield | 5.99% |
| Dividend Yield | 2.21% |
| ROE | 16.06% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | -37.31% |
| Price To Book | 3.67 |
| Price Earnings Ratio | 23.64 |
| Price To FCF | 16.71 |
| Price To sales | 1.85 |
| EV / EBITDA | 6.36 |
News
- Nov -17 - Dermapharm Holding Third Quarter 2024 Earnings: EPS: €0.60 (vs €0.46 in 3Q 2023)
- Oct -11 - Dermapharm Holding (ETR:DMP) stock falls 4.9% in past week as three-year earnings and shareholder returns continue downward trend
- Aug -31 - Revenue Beat: Dermapharm Holding SE Exceeded Revenue Forecasts By 6.7% And Analysts Are Updating Their Estimates
- Apr -13 - Should You Be Impressed By VEON Ltd.'s (NASDAQ:VEON) ROE?
- Apr -09 - Those who invested in Geberit (VTX:GEBN) five years ago are up 39%
- Mar -29 - Dermapharm Holding Full Year 2023 Earnings: EPS: €1.16 (vs €2.49 in FY 2022)
- Nov -03 - As Tecan Group (VTX:TECN) lifts 4.9% this past week, investors may now be noticing the company's three-year earnings growth
- Sep -26 - Is Dermapharm Holding SE (ETR:DMP) Trading At A 39% Discount?
- Sep -17 - Is Autoneum Holding AG's (VTX:AUTN) 17% ROE Better Than Average?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Branded Medicine
Expected Growth : 6 %
What the company do ?
Dermapharm Holding SE's branded medicine segment offers a range of pharmaceutical products, including prescription and over-the-counter medications, focusing on dermatology, neurology, and other therapeutic areas.
Why we expect these perspectives ?
Dermapharm Holding SE's branded medicine segment growth is driven by increasing demand for dermatology and skincare products, expansion into new markets, strategic acquisitions, and a strong product pipeline. Additionally, growing awareness of skin health and rising disposable incomes in emerging markets contribute to the 6% growth rate.
Segment n°2 -> Other Health Products
Expected Growth : 4 %
What the company do ?
Dermapharm Holding SE's Other Health Products segment includes a range of over-the-counter (OTC) pharmaceuticals, medical devices, and food supplements for various health and wellness needs.
Why we expect these perspectives ?
Dermapharm Holding SE's Other Health Products segment growth is driven by increasing demand for self-care and preventive healthcare, expansion into new markets, and strategic acquisitions. Additionally, the company's focus on R&D and innovative product offerings, such as dietary supplements and medical devices, contribute to its growth.
Segment n°3 -> Parallel Import
Expected Growth : 3 %
What the company do ?
Parallel Import from Dermapharm Holding SE refers to the importation and distribution of original pharmaceutical products from Germany, ensuring authenticity and quality.
Why we expect these perspectives ?
Dermapharm Holding SE's parallel import segment growth is driven by increasing demand for affordable healthcare products, strategic partnerships, and expansion into new markets. Additionally, the company's focus on digitalization and e-commerce platforms has enhanced customer reach and convenience, contributing to the 3% growth rate.
Dermapharm Holding Se Products
| Product Range | What is it ? |
|---|---|
| Branded Pharmaceuticals | Dermapharm Holding SE develops and markets branded pharmaceuticals for the treatment of various diseases, including dermatological, cardiovascular, and neurological disorders. |
| Herbal Remedies | The company offers a range of herbal remedies for the treatment of various health conditions, including digestive issues, sleep disorders, and stress relief. |
| Dietary Supplements | Dermapharm Holding SE provides a variety of dietary supplements for maintaining overall health and wellness, including vitamins, minerals, and other nutritional products. |
| Cosmetics | The company develops and markets a range of cosmetics and skincare products, including creams, lotions, and serums for various skin types and conditions. |
| Prescription-Free Medicines | Dermapharm Holding SE offers a range of prescription-free medicines for the treatment of common ailments, including pain relief, cold and flu, and allergy relief. |
Dermapharm Holding SE's Porter Forces
Threat Of Substitutes
Dermapharm Holding SE operates in the pharmaceutical industry, where substitutes are available, but the company's strong brand presence and product offerings mitigate the threat.
Bargaining Power Of Customers
Dermapharm Holding SE's customers are primarily pharmacies and wholesalers, who have limited bargaining power due to the company's strong market position and diversified product portfolio.
Bargaining Power Of Suppliers
Dermapharm Holding SE relies on a diverse supplier base, which reduces the bargaining power of individual suppliers. However, the company is still exposed to supplier concentration risks.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including regulatory hurdles and significant R&D investments, which limits the threat of new entrants for Dermapharm Holding SE.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players competing for market share. Dermapharm Holding SE faces intense rivalry from other companies, which may impact its market position and pricing power.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 66.43% |
| Debt Cost | 8.50% |
| Equity Weight | 33.57% |
| Equity Cost | 9.20% |
| WACC | 8.74% |
| Leverage | 197.91% |
Dermapharm Holding SE : Quality Control
Dermapharm Holding SE passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PRGO | Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through … |
| ALM.MC | Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for … |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North … |
| SFZN.SW | Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral … |
| ALVO | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Dermapharm Holding
A-Score
1-Year Total Return ->
🥈
Almirall
A-Score
1-Year Total Return ->
🥉
Siegfried Holding
A-Score
1-Year Total Return ->
4
Sobi
A-Score
1-Year Total Return ->
5
Alvotech
A-Score
1-Year Total Return ->
6
